Quick Answer
Beam Therapeutics Inc. reported Cash and Equivalents of $294.94 million for fiscal year 2025.
Beam Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $294.94M | +4.6% |
| 2024 | $281.97M | -35.3% |
| 2023 | $435.89M | +87.3% |
| 2022 | $232.77M | -58.4% |
| 2021 | $559.99M | +245.3% |
| 2020 | $162.17M | +335.7% |
| 2019 | $37.22M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $267.96M | +16.4% | -5.0% |
| June 30, 2025 | $282.13M | -3.6% | -46.6% |
| March 31, 2025 | $527.91M | +83.4% | +87.2% |
| December 31, 2024 | $281.97M | -35.3% | +22.5% |
| September 30, 2024 | $230.20M | +36.2% | -21.4% |
| June 30, 2024 | $292.76M | +29.8% | +1.7% |
| March 31, 2024 | $287.85M | +15.2% | -34.0% |
| December 31, 2023 | $435.89M | +87.3% | +157.9% |
- Beam Therapeutics Inc. showed an increase of +4.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Beam Therapeutics Inc.’s cash and equivalents has grown by 692.4% (from $37.22 million to $294.94 million).
- The most recent figure is from Beam Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: